Medical/Pharmaceuticals

Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

TOKYO, Jan. 10, 2023 /PRNewswire/ -- Ajinomoto Co., Inc. ("Ajinomoto Co.") today announced a license agreement with Exelixis, Inc. ("Exelixis") to incorporate AJICAP®, Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' ant...

2023-01-10 21:05 2496

Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors

* Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology market * FDA market authorization advances personalized cancer care in Asia * Clearance sets the stage for continued R&D investment into early d...

2023-01-10 21:05 2913

Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients

ROSCREA, Ireland, Jan. 10, 2023 /PRNewswire/ – Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal ("GI") disorders, is pleased to announce opening of the Investigational New Drug ...

2023-01-10 21:00 2645

EpiVax and Zoetis to Collaborate on Swine T cell Epitope Prediction Tool: CircoMatch™

PROVIDENCE, R.I., Jan. 10, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and Zoetis, are pleased to announce an exclusive collaboration to develop CircoMatch™, a unique bioinformatics tool that predicts the coverage of Porcine Circovirus Type 2 (PCV2) vaccines against field isolates of PCV2. The n...

2023-01-10 21:00 3443

Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer

NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CFI-402257, a best in class inhibitor of Threonine Tyrosine Kinase (TTK, also known as Mps...

2023-01-10 21:00 2964

Complete Genomics Launches Full Sequencing Platforms at Biotech Showcase™ 2023

SAN FRANCISCO, Jan. 10, 2023 /PRNewswire/ -- Complete Genomics Inc ( https://completegenomics.mgiamericas.com/ ), a subsidiary of MGI Tech Co., Ltd. ("MGI"), today unveiled its full sequencing platforms at Biotech Showcase during JP Morgan Healthcare...

2023-01-10 20:30 2945

CSafe Bolsters Its Digital Ecosystem Launching TracSafe Data Loggers and CSafe Connect Portal

TracSafe fit-for-purpose data loggers link directly to the comprehensive CSafe Connect customer portal creating the next iteration of a progressive customer-focused digital ecosystem MONROE, Ohio, Jan. 10, 2023 /PRNewswire/ -- CSafe, the largest provider of a complete range of active and passive ...

2023-01-10 20:00 3302

Sarah Otten Joins Medison Pharma as VP, GM Americas Region

Sarah Otten will lead Medison's Americas region covering Canada and Latin America. Sarah brings vast geographical expansion experience in international markets. PETACH TIKVAH, Israel and ZUG, Switzerland, Jan. 9, 2023 /PRNewswire/ -- Medison Pharma ("Medison"), a...

2023-01-10 19:54 2167

Clarivate Identifies Fifteen Potential Blockbuster Drugs in Annual Drugs to Watch Report

Report highlights personalized medicines ensuring greater efficacy for rare diseases and previously untreatable conditions Promising therapeutic developments for HIV, Parkinson's disease, Crohn's disease, alopecia, multiple myeloma and breast cancer on horizon LONDON, Jan. 10, 2023 /PRNewswire/ ...

2023-01-10 16:00 1904

Appointment of Dr. David John Jeans CBE as HistoIndex's Non-Executive Chairman

SINGAPORE, Jan. 10, 2023 /PRNewswire/ -- The Board of Directors (the "Board") of HistoIndex (the "Company") would like to announce the following changes in appointments to the Board with effect from6th December 2022: (1) Mr Sim Giok Lak's decision to step down as Non-Executive Chairman of the Bo...

2023-01-10 13:01 1850

Bangkok Dusit Medical Services extends partnership with CNN to explore global health issues

HONG KONG, Jan. 10, 2023 /PRNewswire/ -- Bangkok Dusit Medical Services Public Company Limited (BDMS), the largest healthcare network inThailand, reinforces its long-standing partnership with CNN International Commercial (CNNIC) with the sponsorship of 'Vital Signs

2023-01-10 11:24 2457

Lydus Medical Announces FDA Clearance of Vesseal™, The Microvascular Anastomosis Aid Device for Small Arteries

RA'ANANA, Israel, Jan. 10, 2023 /PRNewswire/ -- Lydus Medical is pleased to announce that the Vesseal™ has received FDA clearance 510(k). The Vesseal™ is a microvascular anastomosis suture deployment system, for standardized omni-vessel anastomoses, enabling simp...

2023-01-10 09:00 1990

Insilico Medicine Announces Positive Topline Results of the New Zealand Phase I Trial of INS018_055, an AI-Designed Drug for an AI-Discovered Target

NEW YORK and HONG KONG, Jan. 10, 2023 /PRNewswire/ -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug R&D company, today announces positive topline results of safety, tolerability, and pharmacokinetics (PK) from thePhase I clinical trial of INS018_055

2023-01-10 05:00 4005

The Latest Global Survey from ISAPS Reports a Significant Rise in Aesthetic Surgery Worldwide

Total surgical and non-surgical procedures increased by 19.3% MOUNT ROYAL, N.J., Jan. 10, 2023 /PRNewswire/ -- The International Society of Aesthetic Plastic Surgery (ISAPS) released the results of its annual Global Survey on Aesthetic/Cosmetic Procedures today, showing a 19.3% overall increase ...

2023-01-10 00:16 2934

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

ROCKVILLE, Md. and SUZHOU, China, Jan. 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2023-01-10 00:00 3264

Shanton Screens First Subjects in Phase 2b Refractory/Tophaceous Gout Study with SAP-001

SAP-001 is an oral once-a-day investigational gout product with Best-in-Class potential for acute and chronic use in uncontrolled patients BRIDGEWATER, N.J., Jan. 9, 2023 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a groundbreaking treatment for refractory and top...

2023-01-09 22:00 2409

Gift of Life Donor Program: Nation's Leader for 15 Years

Gift of Life Staff, Community & Hospital Partners Continue Proud History of Saving Lives Together PHILADELPHIA, Jan. 9, 2023 /PRNewswire/ -- Gift of Life Donor Program continues to lead the U.S. in life-saving organ donations for a milestone 15 consecutive years thanks to its dedicated staff, ho...

2023-01-09 22:00 2842

Mars Petcare and the Broad Institute create open-access database of dog and cat genomes to advance preventive pet care

* The genome database will power ongoing scientific efforts worldwide and help advance individualized pet health care * Insights from this partnership will feed into the MARS PETCARE BIOBANK™, a longitudinal study to understand pet health and disease, transforming pet care for future generati...

2023-01-09 21:15 2400

SoniVie Raises $60m in Round C Financing, and Appoints New Board Members

The funds, provided by new investors and current shareholder, will be used to support the Company clinical and regulatory path towards pre-market approval of its TIVUS™ technology for the treatment of hypertension TEL AVIV, Israel, Jan. 9, 2023 /PRNewswire/ -- SoniVie Ltd.

2023-01-09 20:00 2733

Luye Pharma's Innovative Anti-Cancer Therapy Lurbinectedin to Benefit "Named Patients" in Hong Kong

HONG KONG, Jan. 9, 2023 /PRNewswire/ -- Luye Pharma Group today announced the launch of the Named Patient Program (NPP) inHong Kong, China, providing eligible local patients immediate access to the innovative anti-cancer therapy Lurbinectedin. Luye Pharma has signed an agreement with Abacus Medic...

2023-01-09 18:57 3504
1 ... 138139140141142143144 ... 398